Cannabinoids

Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery

Volumn , Issue , 2003, Pages 683-706

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847785979     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (169)

1. 2 receptors. Pharmacol Ther 1997; 74:129180.
2. Pertwee RG. Advances in cannabinoid receptor pharmacology. In: Brown D, ed. Cannabis. The Genus Cannabis. Harwood Academic, 1998:125-174.
3. 1 receptors in the rat central nervous system. Neuroscience 1998; 83:393-411.
4. 2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284:644650.
5. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38:151-178.
6. 6-THC-7-oic acid. Agents Actions 1990; 31:157-163.
7. Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, Mechoulam R. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chern 1992; 35:3135-3141.
8. 3) in mice. Life Sci 1998; 63:161-168.
9. Burstein SH. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 1999; 82:87-96.
10. 9-tetrahydrocannabinol (THC). J Pharmacol Exp Ther 1973; 186:646-655.
11. Melvin LS, Johnson MR, Harbert CA, Milne GM, Weissman A. A cannabinoid derived prototypical analgesic. J Med Chern 1984; 27:67-71.
12. Weissman A, Milne GM, Melvin LS. Cannabimimetic activity from CP-47, 497, a derivative of 3phenylcyclohexanol. J Pharmacol Exp Ther 1982; 223:516-522.
13. Vitez TS, Way WL, Miller RD, Eger EI. Effects of delta-9-tetrahydrocannabinol on cyclopropane MAC in the rat. Anesthesiology 1973; 38:525-527.
14. Stoelting RK, Martz RC, Gartner J, Creasser C, Brown DJ, Forney RB. Effects of delta-9-tetrahydrocannabinol on halothane MAC in dogs. Anesthesiology 1973; 38:521-524.
15. 9-tetrahydrocannabinol in the mouse. Eur J Pharmacol 1980; 68:147-154.
16. 9-tetrahydrocannabinol in the mouse. Psychopharmacology 1978; 57:243-248.
17. 9-tetradrocannabinol in the rat and mouse. Psychopharmacologia 1972; 25:275-280.
18. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 1992; 260: 201-209.
19. 9_ tetrahydrocannabinol. Gen Pharmacol 1983; 14:247-252.
20. Dewey WL, Harris LS, Howes JF, Kennedy JS, Granchelli FE, Pars HG, Razdan RK. Pharmacology of some marijuana constituents and two heterocyclic analogues. Nature 1970; 226:1265-1267.
21. 9-tetrahydrocannabinol in laboratory rodents. Arch Int Phannacodyn 1972; 196: 133-145.
22. Koe BK, Milne GM, Weissman A, Johnson MR, Melvin LS. Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics. Eur J Phannacol 1985; 109: 201-212.
23. Lichtman AH, Smith FL, Martin BR. Evidence that the antinociceptive tail-flick response is produced independently from changes in either tail-skin temperature or core temperature. Pain 1993; 55:283-295.
24. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. Phannacology and stereoselectivity of structurally novel cannabinoids in mice. J Phannacol Exp Ther 1988; 247:1046-1051.
25. Martin BR. Charaterization of the antinociceptive activity of intravenously administered delta-9tetrahydrocannabinol in mice. In: Harvey DJ, ed. Marihuana '84. Oxford: IRL Press, 1985:685692.
26. Martin BR. Structural requirements for cannabinoid-induced antinoceptive activity in mice. Life Sci 1985; 36:1523-1530.
27. 9-THC. Phannacol Biochem Behav 1993; 46:295-301.
28. Pertwee RG, Browne SE, Ross TM, Stretton CD. An investigation of the involvement of GABA in certain phannacological effects of delta-9-tetrahydrocannabinol. Phannacol Biochem Behav 1991; 40:581-585.
29. 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of µ-and K-opioid receptors. Eur J Phannacol 1996; 318:11-16.
30. 9-tetrahydrocannabinol-induced analgesia in mice. Eur J Phannacol 1996; 301:75-81.
31. 9-tetrahydrocannabinol-induced analgesia. Brain Res 1992; 578:8-12.
32. 9-tetrahydrocannabinol in mice and rats. Phannacology 1983; 27:223-236.
33. 9-THC. Eur J PhannacoI1972; 19:310-317.
34. 9-tetrahydrocannabinol in mice. Brain Res 1994; 667:77-82.
35. 9_ tetrahydrocannabinol in mice. Eur J Phannacol 1994; 260:5-13.
36. Welch SP. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N, Ndiallyl-tyrosine-Aib-phenylalanine-Ieucine, ICI 174,864, or naloxone in mice. J Phannacol Exp Ther 1993; 265:633-640.
37. 9-tetrahydrocannabinol (THC) in the rat. Asia Pac J Phannacol 1989; 4: 179-188.
38. Gallager DW, Sanders-Bush E, Sulser F. Dissociation between behavioural effects and changes in metabolism of cerebral serotonin following d 9-tetrahydrocannabinol. Psychophannacologia 1972; 26:337-345.
39. 9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart-rate responses in the rat. Psychopharmacology 1985; 87:34-38.
40. Lichtman AH, Martin BR. Cannabinoid-induced antinociception is mediated by a spinal uTnoradrenergic mechanism. Brian Res 1991; 559:309-314.
41. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 1991; 258:517-523.
42. Lichtman AH, Martin BR. The selective cannabinoid antagonist SR 141716A blocks cannabinoidinduced antinociception in rats. Phannacol Biochem Behav 1997; 57:7-12.
43. Novelli GP, Peduto VA, Bertol E, Marl F, Pieraccioli E. Analgesic interaction between nitrous oxide and delta-9-tetrahydrocannabinol. Br J Anaesth 1983; 55:997-1000.
44. Burstein SH, Hull K, Hunter SA, Latham V. Cannabinoids and pain response: a possible role for prostaglandins. FASEB J 1988; 2:3022-3026.
45. Kaymakcalan S, Deneau GA. Some phannacologic properties of synthetic delta-9-tetrahydrocannabinol. Acta Med Turc SupplI972; 1:5-27.
46. Segelman AB, Sofia RD, Segelman FP, Harakal JJ, Knobloch LC. Cannabis sativa L. (marijuana) V: phannacological evaluation of marijuana aqueous extract and volatile oil. J Phann Sci 1974; 63:962-964.
47. Sofia RD, Vassar HB, Knobloch LC. Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats. Psychophannacologia 1975; 40:285-295.
48. 9-tetrahydrocannabinol. Psychophannacologia 1975; 41:277-284.
49. Wilson RS, May EL. Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs. J Med Chern 1975; 18:700-703.
50. 9-tetrahydrocannabinolin rats. Eur J Phannacol 1981; 70:219-224.
51. Gilbert PE. A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dog. J Clin Phannacol 1981; 21:311S-319S.
52. Formukong EA, Evans AT, Evans FJ. Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 1988; 12:361-371.
53. 9-tetrahydrocannabinol on intestinal motility and on the abdominal constriction response in the mouse. Psychophannacology 1976; 47:187-193.
54. 9-tetrahydrocannabinol and some synthetic analogues. J Med Chern 1978; 21:809-811.
55. Sanders J, Jackson DM, Starmer GA. Interactions among the cannabinoids in the antagonism of the abdominal constriction response in the mouse. Psychophannacology 1979; 61:281-285.
56. Watanabe K, Kijima T, Narimatsu S, Nishikarni J, Yamamoto I, Yoshimura H. Comparison of phannacological effects of tetrahydrocannabinols and their ll-hydroxy-metabolites in mice. Chern Pharm Bull 1990; 38:2317-2319.
57. Welbum PJ, StarmerGA, ChesherGB, Jackson DM. Effectofcannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychophannacologia 1976; 46:83-85.
58. 9-tetrahydrocannabinolas measured with the formalin test. Eur J Pharmacol 1980; 61:313-315.
59. 9_ tetrahydrocannabinol in the rat. Eur J Phannacoll 973; 24:1-7.
60. 9-tetrahydrocannabinoland anandarnide antinociception in non-arthritic and arthritic rats. Phannacol Biochem Behav 1998; 60: 183191.
61. 9_THc. Int J Clin Phannacol Ther Toxicol 1973; 7:75-81.
62. Scheckel CL, Boff E, Dahlen P, Smart T. Behavioral effects in monkeys of racemates of two biologically active marijuana constituents. Science 1968; 160:1467-1469.
63. Bicher HI, Mechoulam R. Pharmacological effects of two active constituents of marihuana. Arch Int Phannacodyn 1968; 172:24-31.
64. 9-tetrahydrocannabinolin the dog. Psychophannacologia 1974; 35:123-128.
65. Martin BR, Thomas BF, Razdan RK. Structural requirements for cannabinoid receptor probes. In: Pertwee RG, ed. Cannabinoid Receptors. London: Academic, 1995:35-85.
66. 9-THC: reassessment of the putative three-point cannabinoid-receptor interaction. Drug Alcohol Depend 1995; 37:231-240.
67. 9-tetrahydrocannabinols. Eur J Med Chern 1997; 32:165-170.
68. 8-tetrahydrocannabinol. Neuropharmacology 1996; 35:1793-1804.
69. 2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996; 278:989-999.
70. 2 receptor. J Med Chern 1996; 39:3875-3877.
71. Huffman JW, Lainton JAH. Recent developments in the medicinal chemistry of cannabinoids. Curr Med Chern. 1996; 3:101-116.
72. Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from d 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1992; 263:1118-1126.
73. Kumar V, Alexander MD, Bell MR, Eissenstat MA, Casiano PM, Chippari SM, Haycock DA, Luttinger DA, Kuster JE, Miller MS, Stevenson JL, Ward SJ. Morpholinoalkylindenes as antinociceptive agents: novel cannabinoid receptor agonists. Bioorg Med Chern Lett 1995; 5:381-386.
74. Wiley JL, Compton DR, Dai D, Lainton JAR, Phillips M, Huffman JW, Martin BR. Structureactivity relationships of indole-and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 1998; 285: 995-1004.
75. Dutta AK, Ryan W, Thomas BF, Singer M, Compton DR, Martin BR, Razdan RK. Synthesis, pharmacology, and molecular modeling of nove 14-alkyloxy indole derivatives related to cannabirnimetic aminoa1kyl indoles (AAIs). Bioorg Med Chern 1997; 5:1591-1600.
76. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994; 270:219-227.
77. Adams IB, Compton DR, Martin BR. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 1998; 284:1209-1217.
78. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50:83-90.
79. 9-THC after intrathecal administration to mice: blockade of d 9-THC-induced antinociception. J Pharmacol Exp Ther 1995; 273:1235-1244.
80. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993; 231:313-314.
81. Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, Martin BR. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 1995; 273: 1172-1181.
82. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394:277-281.
83. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chern 1994; 37:1889-1893.
84. Barg J, Fride E, Hanus L, Levy R, Matus-Leibovitch N, Heldman E, Bayewitch M, Mechoulam R, Vogel Z. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol 1995; 287:145-152.
85. Ryan WJ, Banner WK, Wiley JL, Martin BR, Razdan RK. Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. J Med Chern 1997; 40:3617-3625.
86. Smith PB, Welch SP, Martin BR. Interactions between d 9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 1994; 268:1381-1387.
87. 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 1996;279:608-616.
88. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 1996; 276:585-593.
89. 9-THC-induced antinociceptive tolerance. Pharmacol Biochem Behav 1998; 59: 399-404.
90. Little PJ, Compton DR, Mechoulam R, Martin BR. Stereochemical effects of 1l-OH-L\8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav 1989; 32:661-666.
91. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, Ward SJ. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 1991; 40:471-478.
92. Compton DR, Rice KC, de Costa BR, Razdan RK, Melvin LS, Johnson MR, Martin BR. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993; 265:218-226.
93. Melvin LS, Milne GM, Johnson MR, Subramaniam B, Wilken GH, Howlett AC. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 1993; 44:1008-1015.
94. Tsou K, Lowitz KA, Hohmann AG, Martin WJ, Hathaway CB, Bereiter DA, Walker 1M. Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 1996; 70:791-798.
95. Yan G, Yin D, Khanolkar AD, Compton DR, Martin BR, Makriyannis A. Synthesis and pharmacological properties of II-hydroxy-3-(1 ',1'-dimethylheptyl)hexahydrocannabinol: a high-affinity cannabinoid agonist. J Med Chern 1994; 37:2619-2622.
96. Compton DR, Aceto MD, Lowe J, Martin BR. In vivo characterization of a specific cannabinoid receptor antagonist (SR 141716A): inhibition of L\9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996; 277:586-594.
97. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur G. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350:240-244.
98. Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 1998; 242:33-36.
99. Yaksh TL. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J Clin Pharmacol 1981; 21:334S-340S.
100. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 1992; 262:10-18.
101. Welch SP, Thomas C, Patrick GS. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 1995; 272:310-321.
102. Martin WJ, Lai NK, Patrick SL, Tsou K, Walker JM. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res 1993; 629:300-304.
103. Lichtman AH, Smith PB, Martin BR. The antinociceptive effects of intrathecally administered cannabinoids are influenced by lipophilicity. Pain 1992; 51:19-26.
104. Edsall SA, Knapp RJ, Vanderah TW, Roeske WR, ConsroeP, Yamamura HI. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. Neuroreport 1996; 7:593-596.
105. Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 1996; 16:6601-6611.
106. Pugh G, Mason DJ, Combs V, Welch SP. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J Pharmacol Exp Ther 1997; 281:730-737.
107. 9-THC in the spinal cord. Brain Res 1995; 689:157-158.
108. 9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci 1997; 61:PL39-PlA3.
109. Manzanares J, Corchero J, Romero J, Femandez-Ruiz JJ, Ramos JA, Fuentes JA. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Mol Brain Res 1998; 55:126-132.
110. Pertwee RG. Tolerance to and dependence on psychotropic cannabinoids. In: Pratt JA, ed. The Biological Bases of Drug Tolerance and Dependence. London: Academic, 1991:231-263.
111. 9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998; 60:559-566.
112. Ghosh P, Bhattacharya SK. Cannabis-induced potentiation of morphine analgesia in rat-role of brain monoarnines. Ind J Med Res 1979; 70:275-280.
113. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB I receptors. Pain 1998; 75:111-119.
114. Richardson JD, Aanonsen L, Hargreaves KM. Antithyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998; 345:145-153.
115. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997; 221: 157-160.
116. Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 1998; 18:451-457.
117. Welch SP. Blockade of cannabinoid-induced antinociception by naloxone benzoylhydrazone (NalBZH). Pharmacol Biochem Behav 1994; 49:929-934.
118. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandarnide and palmitoylethanolarnide. Proc Natl Acad Sci USA 1995; 92:3376-3380.
119. 2 receptor agonist palmitoylethanolarnide in visceral and somatic inflammatory pain. Pain 1998; 76:189-199.
120. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand J-P, Le Fur G, Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor J. Evidence for a new model of receptor/ligand interactions. J BioI Chem 1997; 272:22330-22339.
121. 2 receptors. Br J Pharmacol 1998; 124:619622.
122. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997; 319:R3-R4.
123. Hill SY, Schwin R, Goodwin DW, Powell BJ. Marihuana and pain. J Pharmacol Exp Ther 1974; 188:415-418.
124. Hill SY, Goodwin DW, Schwin R, Powell B. Marijuana: CNS depressant or excitant? Am J Psychiatry 1974; 131:313-315.
125. Clark WC, Janal MN, Zeidenberg P, Nahas GG. Effects of moderate and high doses of marihuana on thermal pain: a sensory decision theory analysis. J Clin Pharmacol 1981; 21:299S-31OS.
126. Milstein SL, MacCannell KL, Karr GW, Clark S. Marijuana produced changes in cutaneous sensitivity and affect: users and non-users. Pharmacol Biochem Behav 1974; 2:367-374.
127. 9-tetrahydrocannabinol and cannabinol in man. Pharmacology 1975; 13:502-512.
128. Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of analgesic response. Clin Pharmacol Ther 1977; 21:26-33.
129. 9-Tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Braude MC, Szara S, eds. Pharmacology of Marihuana. New York: Raven, 1976:763-776.
130. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21:320S-326S.
131. Grinspoon L, Bakalar JB. Marihuana, the Forbidden Medicine. New Haven: Yale University Press, 1993.
132. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38:44-48.
133. Dunn M, Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia 1979; 12:175.
134. Finnegan-Ling D, Musty RE. Marinol and phantom limb pain: a case study. Proc Int Cannabinoid Res Soc 1994; 53.
135. Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M, Evans F. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997; 52:483-488.
136. 9-tetrahydrocannabino1.J Clin Pharmacol 1975; 15:139-143.
137. Noyes R, Brunk SF, Avery DH, Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18:84-89.
138. Maurer M, Henn V, Dittrich A, Hofmann A. delta-9-Tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Archs Psychiatry Clin Neurosci 1990; 240: 1-4.
139. 9-tetrahydrocannabinolon spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996; 34:446-452.
140. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995; 345: 579.
141. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophrenia Res 1995; 15:277281.
142. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38:1-20.
143. Munson AE, Fehr KO. Immunological effects of cannabis. In: Fehr KO, Kalant H, eds. Adverse Health and Behavioral Consequences of Cannabis Use. Toronto: Addiction Research Foundation, 1983:257-353.
144. Jones RT. Cannabis tolerance and dependence. In: Fehr KO, Kalant H, eds. Toronto: Addiction Research Foundation, 1983; 617-689.
145. Jones RT, Benowitz N. The 30-day trip-clinical studies of cannabis tolerance and dependence. In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York: Raven, 1976:627-642.
146. Pertwee RG. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Pharm Sci 1997; 3:539-545.
147. 9-tetrahydrocannabino1. Psychopharmacologia 1973; 33:53-70.
148. Zeltser R, Seltzer Z, Eisen A, Feigenbaum JJ, Mechoulam R. Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain 1991; 47:95-103.
149. Pertwee RG. Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors. Biochem Soc Tran 1998; 26:267-272.
150. Martin BR, Lichtman AH. Cannabinoid transmission and pain perception. Neurobiol Dis 1998; 5: 447-461.
151. Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K. The neurobiology of cannabinoid analgesia. Life Sci 1999; 65:665-673.
152. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobio 12001; 63:569-611.
153. Walker JM, Huang SM, Strangrnan NM, Tsou K, Saiiudo-Peiia MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999; 96:12198-12203.
154. Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM. Anatomical basis for cannabinoidinduced antinociception as revealed by intracerebral microinjections. Brain Res 1999; 822:237242.
155. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 1998; 395:381-383.
156. Hohmann AG, Tsou K, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal hom of the rat. J Neurophysiol 1999; 81:575583.
157. Hohmann AG, Tsou K, Walker JM. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal hom of the rat by spinally administered WIN 55,212-2. Neurosci Letts 1998; 257: 119-122.
158. Hohmann AG, Herkenham M. Localization of central cannabinoid CB J receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 1999; 90:923-931.
159. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999; 92: 1171-1175.
160. Hohmann AG, Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci Lett 1998; 252:13-16.
161. Hohmann AG, Briley EM, Herkenham M. Pre-and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999; 822: 17-25.
162. Ko M-C, Woods JH. Local administration of d 9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology 1999; 143:322-326.
163. Li J, Daughters RS, Bullis C, Bengiamin R, Stucky MW, Brennan J, Simone DA. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 1999; 81:25-33.
164. Strangman NM, Walker JM. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol 1999; 82:472-477.
165. Chapman V. The cannabinoid CB J receptor antagonist, SR 141716A, selectively facilitates nociceptive responses of dorsal hom neurones in the rat. Br J Pharmacol 1999; 127:1765-1767.
166. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sfrgard M, Di Marzo V, Julius D, Hogestiitt ED. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400:452-457.
167. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2002; 66: 101-121.
168. Ledent C, Valverde O, Cossu C, Petitet F, Aubert L-F, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB I receptor knockout mice. Science 1999; 283:401-404.
169. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB I receptor knockout mice. Proc Natl Sci USA 1999; 96: 5780-5785.